The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease
Open accessAbstract
IMPORTANCE: Proton pump inhibitors (PPIs) are among the most commonly used drugs worldwide and have been linked to acute interstitial nephritis. Less is known about the association between PPI use and chronic kidney disease (CKD). OBJECTIVE: To quantify the association between PPI use and incident CKD in a population-based cohort. DESIGN, SETTING, AND PARTICIPANTS: In total, 10,482 participants in the Atherosclerosis Risk in Communities study with an estimated glomerular filtration rate of at least 60 mL/min/1.73 m(2) were followed from a baseline visit between February 1, 1996, and January 30, 1999, to December 31, 2011. The data was analyzed from May 2015 to October 2015. The findings were replicated in an administrative cohort of 248,751 patients with an estimated glomerular filtration rate of at least 60 mL/min/1.73 m(2) from the Geisinger Health System. EXPOSURES: Self-reported PPI use in the Atherosclerosis Risk in Communities study or an outpatient PPI prescription in the Geisinger Health System replication cohort. Histamine2 (H2) receptor antagonist use was considered a negative control and active comparator. MAIN OUTCOMES AND MEASURES: Incident CKD was defined using diagnostic codes at hospital discharge or death in the Atherosclerosis Risk in Communities Study, and by a sustained outpatient estimated glomerular filtration rate of less than 60 mL/min/1.73 m(2) in the Geisinger Health System replication cohort. RESULTS: Among 10,482 participants in the Atherosclerosis Risk in Communities study, the mean (SD) age was 63.0 (5.6) years, and 43.9% were male. Compared with nonusers, PPI users were more often of white race, obese, and taking antihypertensive medication. Proton pump inhibitor use was associated with incident CKD in unadjusted analysis (hazard ratio [HR], 1.45; 95% CI, 1.11-1.90); in analysis adjusted for demographic, socioeconomic, and clinical variables (HR, 1.50; 95% CI, 1.14-1.96); and in analysis with PPI ever use modeled as a time-varying variable (adjusted HR, 1.35; 95% CI, 1.17-1.55). The association persisted when baseline PPI users were compared directly with H2 receptor antagonist users (adjusted HR, 1.39; 95% CI, 1.01-1.91) and with propensity score-matched nonusers (HR, 1.76; 95% CI, 1.13-2.74). In the Geisinger Health System replication cohort, PPI use was associated with CKD in all analyses, including a time-varying new-user design (adjusted HR, 1.24; 95% CI, 1.20-1.28). Twice-daily PPI dosing (adjusted HR, 1.46; 95% CI, 1.28-1.67) was associated with a higher risk than once-daily dosing (adjusted HR, 1.15; 95% CI, 1.09-1.21). CONCLUSIONS AND RELEVANCE: Proton pump inhibitor use is associated with a higher risk of incident CKD. Future research should evaluate whether limiting PPI use reduces the incidence of CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Self-citationChronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895
Self-citation(1989) · PubMed · Cited by 3,139
Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis
Coca, S. G., Singanamala, S., & Parikh, C. R. (2012) · Kidney International · doi:10.1038/ki.2011.379 · Cited by 2,256
US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States
Saran, R., Robinson, B., Abbott, K. C., Agodoa, L. Y. C., Albertus, P., Ayanian, J., Balkrishnan, R., Bragg-Gresham, J., Cao, J., Chen, J. L. T., et al. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.12.004 · Cited by 2,191
Clinical consequences of polypharmacy in elderly
Maher, R. L., Hanlon, J., & Hajjar, E. R. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.827660 · Cited by 1,938
Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture
Yang, Y.-X., Lewis, J. D., Epstein, S., & Metz, D. C. (2006) · JAMA · doi:10.1001/jama.296.24.2947 · Cited by 1,214
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A., Chertow, G., & Fan, D. (2005) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2004.10.020 · Cited by 773
IMS Institute for Healthcare Informatics
Evans, R. (2014) · Nursing Standard · doi:10.7748/ns2014.04.28.32.30.s36 · Cited by 594
Dial, S. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1040876 · Cited by 577
Overprescribing proton pump inhibitors
Forgacs, I., & Loganayagam, A. (2008) · BMJ · doi:10.1136/bmj.39406.449456.be · Cited by 553
Active-comparator design and new-user design in observational studies
Yoshida, K., Solomon, D. H., & Kim, S. C. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.30 · Cited by 406
Lambert, A. A., Lam, J. O., Paik, J. J., Ugarte-Gil, C., Drummond, M. B., & Crowell, T. A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128004 · Cited by 327
Danaei, G., Tavakkoli, M., & Hernán, M. A. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kwr301 · Cited by 264
Blank, M.-L., Parkin, L., Paul, C., & Herbison, P. (2014) · Kidney International · doi:10.1038/ki.2014.74 · Cited by 213
Inappropriate prescribing of proton pump inhibitors in primary care
Batuwitage, B. T., Kingham, J. G. C., Morgan, N. E., & Bartlett, R. L. (2007) · Postgraduate Medical Journal · doi:10.1136/pgmj.2006.051151 · Cited by 206
Antoniou, T., Macdonald, E. M., Hollands, S., Gomes, T., Mamdani, M. M., Garg, A. X., Paterson, J. M., & Juurlink, D. N. (2015) · CMAJ Open · doi:10.9778/cmajo.20140074 · Cited by 199
Performance and Limitations of Administrative Data in the Identification of AKI
Grams, M. E., Waikar, S. S., MacMahon, B., Whelton, S., Ballew, S. H., & Coresh, J. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07650713 · Cited by 198
Self-citationBJÖRNSSON, E., ABRAHAMSSON, H., SIMRÉN, M., MATTSSON, N., JENSEN, C., AGERFORZ, P., & KILANDER, A. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03084.x · Cited by 186
Prevalence of chronic kidney disease
Bellizzi, V. (2008) · Giornale Italiano di Nefrologia · Cited by 176
Systematic review: proton pump inhibitor‐associated acute interstitial nephritis
SIERRA, F., SUAREZ, M., REY, M., & VELA, M. F. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03407.x · Cited by 160
Park, C. H., Kim, E. H., Roh, Y. H., Kim, H. Y., & Lee, S. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112558 · Cited by 153
Proton pump inhibitors and acute kidney injury: a nested case–control study
Klepser, D. G., Collier, D. S., & Cochran, G. L. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-150 · Cited by 128
Tin, A., Grams, M. E., Maruthur, N. M., Astor, B. C., Couper, D. J., Mosley, T. H., Selvin, E., Coresh, J., & Kao, W. H. L. (2014) · Kidney International · doi:10.1038/ki.2014.331 · Cited by 126
Self-citationProton pump inhibitor‐induced acute interstitial nephritis
Härmark, L., van der Wiel, H. E., de Groot, M., & van Grootheest, A. C. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02927.x · Cited by 108
Perils and pitfalls of long-term effects of proton pump inhibitors
Wilhelm, S. M., Rjater, R. G., & Kale-Pradhan, P. B. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.811206 · Cited by 104
Grams, M. E., Juraschek, S. P., Selvin, E., Foster, M. C., Inker, L. A., Eckfeldt, J. H., Levey, A. S., & Coresh, J. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.03.013 · Cited by 102
Self-citationLeonard, C. E., Freeman, C. P., Newcomb, C. W., Reese, P. P., Herlim, M., Bilker, W. B., Hennessy, S., & Strom, B. L. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3329 · Cited by 100
Continuation of Proton Pump Inhibitors from Hospital to Community
Grant, K., Al-Adhami, N., Tordoff, J. M., et al. (2006) · Pharmacy World & Science · doi:10.1007/s11096-006-9028-4 · Cited by 76
Identification of Incident CKD Stage 3 in Research Studies
Grams, M. E., Rebholz, C. M., McMahon, B. A., Whelton, S. P., Ballew, S. H., Selvin, E., Wruck, L. M., & Coresh, J. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.02.021 · Cited by 72
Self-citationChanges in Prescription Patterns of Acid‐Suppressant Medications by Belgian Pediatricians
Bruyne, P. D., Christiaens, T. C., Stichele, R. V., & Winckel, M. V. (2013) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e3182a3b04e · Cited by 62
Longterm Proton Pump Inhibitor Therapy and Risk of Hip Fracture
Barkin, J. S. (2007) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70245-1 · Cited by 61
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Chronic Kidney Disease Diagnosis and Management: A Review
Chen, T. K., Knicely, D. H., & Grams, M. E. (2019) · JAMA · doi:10.1001/jama.2019.14745 · Cited by 1,811
Self-citationBirnkrant, D. J., Bushby, K., Bann, C. M., Apkon, S. D., Blackwell, A., Brumbaugh, D., Case, L. E., Clemens, P. R., Hadjiyannakis, S., Pandya, S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30024-3 · Cited by 1,370
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
Levin, A., Tonelli, M., Bonventre, J., Coresh, J., Donner, J.-A., Fogo, A. B., Fox, C. S., Gansevoort, R. T., Heerspink, H. J. L., Jardine, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30788-2 · Cited by 919
Self-citationFreedberg, D. E., Kim, L. S., & Yang, Y.-X. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.031 · Cited by 891
Metadata
- Authors
- Lazarus, B., Chen, Y., Wilson, F. P., Sang, Y., Chang, A. R., Coresh, J., & Grams, M. E.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2016-02-01
- Volume
- 176
- Issue
- 2
- Pages
- 238
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2227754270
- Cited by
- 729
- References
- 34
- FWCI
- 91.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.